Evidence-Based Complementary and Alternative Medicine / 2017 / Article / Tab 1

Review Article

The Characteristics of TCM Clinical Trials: A Systematic Review of ClinicalTrials.gov

Table 1

Characteristics of TCM interventional studies.

ParameterNumber/total number (%)
All trials Oct 2000–Sep 2005 Oct 2005–Sep 2010 Oct 2010–Sep 2015

Primary purpose, N
 Treatment970/1270 (76.4)77/95 (81.1)305/396 (77.0)588/779 (75.5)
 Prevention96/1270 (7.6)3/95 (3.2)30/396 (7.6)63/779 (8.1)
 Other purpose168/1270 (13.2)11/95 (11.6)50/396 (12.6)107/779 (13.7)
 Missing36/1270 (2.8)4/95 (4.2)11/396 (2.8)21/779 (2.7)
Phase, N
 Phase 018/1270 (1.4)1/95 (1.1)3/396 (0.8)14/779 (1.8)
 Phase 167/1270 (5.3)12/95 (12.6)23/396 (5.8)32/779 (4.1)
 Phase 1/phase 261/1270 (4.8)10/95 (10.5)24/396 (6.1)27/779 (3.5)
 Phase 2203/1270 (16.0)28/95 (29.5)71/396 (17.9)104/779 (13.4)
 Phase 2/phase 362/1270 (4.9)3/95 (3.2)22/396 (5.6)37/779 (4.7)
 Phase 3131/1270 (10.3)22/95 (23.2)44/396 (11.1)65/779 (8.3)
 Phase 4101/1270 (8.0)1/95 (1.1)23/396 (5.8)77/779 (9.9)
 Missing627/1270 (49.4)18/95 (18.9)186/396 (47.0)423/779 (54.3)
Sex/age, N
 Female206/1270 (16.2)17/95 (17.9)72/396 (18.2)117/779 (15.0)
 Male20/1270 (1.6)1/95 (1.1)6/396 (1.5)13/779 (1.7)
 Both1044/1270 (82.2)77/95 (81.1)318/396 (80.3)649/779 (83.3)
Overall status, N
 Not yet recruiting96/1270 (7.6)1/95 (1.1)9/396 (2.3)86/779 (11.0)
 Recruiting442/1270 (34.8)3/95 (3.2)71/396 (17.9)368/779 (47.2)
 Active, not recruiting76/1270 (6.0)1/95 (1.1)26/396 (6.6)49/779 (6.3)
 Completed574/1270 (45.2)81/95 (85.3)260/396 (65.7)233/779 (29.9)
 Terminated40/1270 (3.1)7/95 (7.4)20/396 (5.1)13/779 (1.7)
 Suspended6/1270 (0.5)1/95 (1.1)3/396 (0.8)2/779 (0.3)
 Withdrawn10/1270 (0.8)1/95 (1.1)4/396 (1.0)5/779 (0.6)
 Enrolling by invitation26/1270 (2.0)03/396 (0.8)23/779 (3.0)
Study result , N
 Has result50/574 (8.7)2/81 (2.5)33/260 (12.7)15/233 (6.4)
DMC, N
 Has DMC637/1270 (50.2)10/95 (10.5)179/396 (45.2)448/779 (57.5)
 No DMC442/1270 (34.8)8/95 (8.4)151/396 (38.1)283/779 (36.3)
 DMC missing191/1270 (15.0)77/95 (81.1)66/396 (16.7)48/779 (6.2)

Only including the completed studies.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.